Aftermarket Performance of Health Care and Biopharmaceutical IPOs: Evidence From ASEAN Countries

We examine the evidence from the long-run abnormal returns using data for 76 health care and biopharmaceutical initial public offerings (IPOs) listed in a 29-year period between 1986 and 2014 in the Association of Southeast Asian Nations (ASEAN) countries such as Indonesia, Malaysia, Singapore, Thai...

Descripción completa

Detalles Bibliográficos
Autores principales: Komenkul, Kulabutr, Kiranand, Santi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5798722/
https://www.ncbi.nlm.nih.gov/pubmed/28853306
http://dx.doi.org/10.1177/0046958017727105

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5798722/
https://www.ncbi.nlm.nih.gov/pubmed/28853306
http://dx.doi.org/10.1177/0046958017727105

Ejemplares similares